pargyline has been researched along with Idiopathic Parkinson Disease in 29 studies
Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The etiology of idiopathic Parkinson's disease remains as an enigma." | 2.41 | [Studies on endogenous toxins as pathogenic factors in idiopathic parkinson's disease]. ( Maruyama, W; Naoi, M, 2000) |
| "Selegiline is a monamine oxidase type B (MAO-B) inhibitor that incorporates a propargyl ring within its molecular structure." | 1.33 | Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. ( Olanow, CW, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (34.48) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 4 (13.79) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Rojas, RJ | 1 |
| Edmondson, DE | 1 |
| Almos, T | 1 |
| Scott, R | 1 |
| Massari, ME | 1 |
| Meiring, L | 1 |
| Petzer, JP | 1 |
| Legoabe, LJ | 1 |
| Petzer, A | 1 |
| Manoharan, A | 1 |
| Oh, JM | 1 |
| Benny, F | 1 |
| Kumar, S | 1 |
| Abdelgawad, MA | 1 |
| Ghoneim, MM | 1 |
| Shaker, ME | 1 |
| El-Sherbiny, M | 1 |
| Almohaimeed, HM | 1 |
| Gahtori, P | 1 |
| Kim, H | 1 |
| Mathew, B | 1 |
| Szkilnik, R | 1 |
| Brus, R | 1 |
| Malinowska-Borowska, J | 1 |
| Nowak, D | 1 |
| Waliczek, M | 1 |
| Kostrzewa, RM | 1 |
| Nowak, P | 1 |
| Huleatt, PB | 2 |
| Khoo, ML | 2 |
| Chua, YY | 1 |
| Tan, TW | 1 |
| Liew, RS | 1 |
| Balogh, B | 1 |
| Deme, R | 1 |
| Gölöncsér, F | 2 |
| Magyar, K | 1 |
| Sheela, DP | 1 |
| Ho, HK | 1 |
| Sperlágh, B | 2 |
| Mátyus, P | 2 |
| Chai, CL | 2 |
| Baranyi, M | 1 |
| Porceddu, PF | 1 |
| Kulcsár, S | 1 |
| Otrokocsi, L | 1 |
| Kittel, Á | 1 |
| Pinna, A | 1 |
| Frau, L | 1 |
| Dunkel, P | 1 |
| Morelli, M | 1 |
| Naoi, M | 3 |
| Maruyama, W | 3 |
| Tatton, W | 1 |
| Chalmers-Redman, R | 1 |
| Tatton, N | 1 |
| Tabakman, R | 1 |
| Lecht, S | 1 |
| Lazarovici, P | 1 |
| Jenner, P | 2 |
| Youdim, MB | 2 |
| Fridkin, M | 1 |
| Zheng, H | 1 |
| Olanow, CW | 1 |
| Dell'Antone, P | 1 |
| IbnLkayat, M | 1 |
| Drago, D | 1 |
| Zatta, P | 1 |
| Yi, H | 1 |
| Akao, Y | 1 |
| Yamaoka, Y | 1 |
| Shamoto-Nagai, M | 1 |
| Parsons, B | 2 |
| Rainbow, TC | 2 |
| Brannan, T | 1 |
| Prikhojan, A | 1 |
| Martínez-Tica, J | 1 |
| Yahr, MD | 1 |
| Matsubara, K | 1 |
| Senda, T | 1 |
| Uezono, T | 1 |
| Awaya, T | 1 |
| Ogawa, S | 1 |
| Chiba, K | 1 |
| Shimizu, K | 1 |
| Hayase, N | 1 |
| Kimura, K | 1 |
| Chacón, JN | 1 |
| Truscott, TG | 1 |
| Susel, Z | 1 |
| Yarnitsky, D | 1 |
| Parenti, M | 1 |
| Flauto, C | 1 |
| Parati, E | 1 |
| Vescovi, A | 1 |
| Groppetti, A | 1 |
| Marsden, CD | 1 |
| Finberg, JP | 1 |
| Eaker, EY | 1 |
| Bixler, GB | 1 |
| Dunn, AJ | 1 |
| Moreshead, WV | 1 |
| Mathias, JR | 1 |
| Reznikoff, G | 1 |
| Manaker, S | 1 |
| Rhodes, CH | 1 |
| Reches, A | 1 |
| Boulton, AA | 1 |
| Wu, PH | 1 |
| Gorkin, VZ | 1 |
| Dandiya, PC | 1 |
| Bhargava, LP | 1 |
7 reviews available for pargyline and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Survival; Glyceraldehyde-3-Phosphate Dehydrogen | 2003 |
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Drug Evaluation, P | 2004 |
[Studies on endogenous toxins as pathogenic factors in idiopathic parkinson's disease].
Topics: Aging; Animals; Apoptosis; Dopamine; Humans; Methyltransferases; Mitochondria; Neurotoxins; Pargylin | 2000 |
[Protective therapy in Parkinson's disease].
Topics: Animals; Humans; Levodopa; Pargyline; Parkinson Disease; Selegiline | 1990 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1986 |
Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease.
Topics: Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Brain; Carbidopa; Dopamine; Droxidopa; Levodop | 1985 |
[New data on monoamine oxidase inhibitors].
Topics: Acridines; Animals; Brain; Cytoplasm; Hydrazines; Iproniazid; Isoquinolines; Liver; Membranes; Mitoc | 1971 |
22 other studies available for pargyline and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries | 2015 |
The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
Topics: Humans; Indans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Propy | 2022 |
Assembling a Cinnamyl Pharmacophore in the C3-Position of Substituted Isatins via Microwave-Assisted Synthesis: Development of a New Class of Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease.
Topics: Antipsychotic Agents; Dopamine Agents; Humans; Isatin; Microwaves; Molecular Docking Simulation; Mon | 2023 |
Ontogenetic manganese exposure with perinatal 6-OHDA lesioning alters behavioral responses of rats to dopamine D₁ and D2 agonist treatments.
Topics: Animals; Behavior, Animal; Desipramine; Dopamine; Dopamine Agonists; Exploratory Behavior; Female; H | 2014 |
Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
Topics: Animals; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; Mice; Molecular S | 2015 |
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Male; Oxidative St | 2016 |
Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.
Topics: Apoptosis; Clinical Trials as Topic; Dopamine; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibito | 2009 |
Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
Topics: Animals; Apoptosis; Enzyme Inhibitors; Humans; Indans; Models, Chemical; Monoamine Oxidase; Monoamin | 2004 |
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Topics: Animals; Brain; Drug Delivery Systems; In Vitro Techniques; Indans; Iron Chelating Agents; Male; Mit | 2004 |
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Pargyline | 2006 |
Acidic vesicles of the endo-exocytic pathways as targets for some anti-monoamine oxidase drugs.
Topics: Acid-Base Equilibrium; Acids; Alzheimer Disease; Amantadine; Animals; Brain; Brain Chemistry; Brain | 2009 |
Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.
Topics: Alkynes; Cell Death; Cell Line, Tumor; Energy Metabolism; Genetic Markers; Glial Cell Line-Derived N | 2007 |
High-affinity binding sites for [3H]MPTP may correspond to monamine oxidase.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Binding Sites; Brain; Monoam | 1984 |
In vivo comparison of the effects of inhibition of MAO-A versus MAO-B on striatal L-DOPA and dopamine metabolism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Clorgyline; Corpus Striatum; Dopamine; Homovanillic Acid; L | 1995 |
L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: a microdialysis study in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Carbolines; Cell Hypoxia; Dopamine; Dose-Response Relationship | 2001 |
Chemically induced Parkinson's disease. III: A study of a possible role of singlet molecular oxygen in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Free Radicals; Lasers; Monoamine Oxidase; Oxygen; Parg | 1991 |
Manganese neurotoxicity: effects of L-DOPA and pargyline treatments.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Drug Syn | 1986 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Hu | 1987 |
Chronic alterations in jejunal myoelectric activity in rats due to MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Catecholamines; Caudate Nucleus; Electromyogr | 1987 |
Similar distribution of monoamine oxidase (MAO) and parkinsonian toxin (MPTP) binding sites in human brain.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Autoradiography; Binding Sites; Brain; Humans; M | 1985 |
Effect of L-DOPA on the synthesis and excretion of tyramine.
Topics: Animals; Brain Stem; Caudate Nucleus; Cerebellum; Dopamine; Humans; Hypothalamus; Levodopa; Octopami | 1974 |
The antiparkinsonian activity of monoamine oxidase inhibitors and other agents in rats and mice.
Topics: Animals; Dextroamphetamine; Diphenhydramine; Imipramine; Iproniazid; Isocarboxazid; Mice; Monoamine | 1968 |